line), and urbanization (percent county pop. living in an urban area) categories to set national quintile cut points. SEER county incidence data were matched with their corresponding national education, poverty, and urbanization quintiles. The highest, middle, and lowest quintiles were compared over time using incidence rate ratio (IRR) and between quintiles by absolute disparity (AD; highest and lowest quintile range difference) and relative disparity (RD; highest and lowest quintile range ratio). Analysis was performed to 95% confidence intervals (CI) using the Tiwari et al. method.
INTRODUCTION AND OBJECTIVES: Implementation of evidenced-based patient-centered care is challenging in clinical settings. Success of such practice changes varies. The purpose of our study was to evaluate implementation strategies to deploy a shared decision aid for localized prostate cancer (LPC).
METHODS: The Personal Patient Profile-Prostate (P3P) is a web-based decision aid with demonstrated efficacy in reducing decisional conflict among men choosing a care plan for LPC. Implementation strategies were co-designed with leaders in six geographically-diverse urology clinics. As part of routine care, men were informed of P3P and offered access via a variety of methods. Physicians received 1-page summaries of P3P patient-generated reports of current symptoms and factors influencing the care decision. Focus groups including physicians, clinic staff and administrators were held at each site to solicit feedback after the implementation period. Access metrics were monitored for up to 6 months. General impressions, common barriers and promoters were identified and synthesized from the focus group data.
RESULTS: Two sites chose written information only to inform men of P3P, 1 site chose email only, 1 site chose email plus phone contact, 1 site chose MD instruction to use, followed by phone and email follow up and 1 site chose in clinic only. Barriers common to all settings included creating new workflows on top of heavy workloads, and staff and administrator misunderstanding of P3P context and resources. Staff inability to identify men with new LPC (vs follow up visits) hampered access. Promoters to successful implementation included an identified clinical lead, physician engagement and phone combined with email contact. Of all men with LPC seen in the clinics, 51% (range 15-98%) were informed of P3P. The highest rates of P3P access outside of clinic and prior to the consult visit (82, 73%) were observed when 2-3 modes of informing were implemented: physician, email and phone invitations. Clinic sites that chose to only provide written material with instruction to access P3P had the lowest access rates (range 0-14%). Physicians appraised the summaries as useful and helpful.
CONCLUSIONS: Despite challenges for clinic staff to add strategies to implement P3P to already heavy workloads, success was realized when physicians engaged and when staff provided follow up contacts to encourage P3P access. New practice changes to implement an evidence-based intervention require multi-modal strategies for early success. Future trials evaluating methods to reduce clinical workload may be of value.
Source of Funding: NIH 5R01NR009692

MP69-19 THE IMPACT OF RACE ON PERCEPTIONS OF ANXIETY AFTER LOCAL THERAPY FOR PROSTATE CANCER
Shilajit Kundu, Vincent Wong, Channa Amarasekera*, Kevin Lewis, Edward Schaeffer, Anthony Schaeffer, Joshua Meeks, David Victorson, James Burns, Sandra Gutierrez, Chicago, IL; Kevin McVary, Springfield, IL; Sarah Psutka, David Cella, Chicago, IL INTRODUCTION AND OBJECTIVES: Despite the potential side effects associated with treating prostate cancer, many men choose treatment over observation. The relative treatment benefits and harms to health related quality of life outcomes (HRQOL) remain poorly understood. In particular, there is a paucity of data detailing the differences in perceived treatment outcomes in African American (AA) and Hispanic men. We prospectively evaluated the functional and psychosocial effects of prostate cancer treatment in men and hypothesize that there may be differences in outcomes in Caucasian men vs. AA/Hispanic men.
METHODS: We enrolled 105 men with recently diagnosed prostate cancer at our institution in an internet-based study which used validated questionnaires to longitudinally assess HRQOL domains such as sexual and urinary function, bowel function, anxiety, and depression, at 1, 3, 6, and 12 months following treatment. Linear mixed models were used to examine changes in self-reported measures at enrollment (pretreatment) and at each post-treatment follow-up assessment. We focused our analysis on the 70 patients who chose radical prostatectomy or radiation therapy as treatment: 55 of these men were non-Hispanic white; 15 were AA or Hispanic.
RESULTS: Despite significant declines in functional outcomes such as erectile function (P<.001 for both groups), anxiety was significantly lowered post-treatment in both groups. Significant reductions in anxiety were noted for Caucasian men (3.9 points, P<0.001) and were even greater for AA/Hispanic men (5.7 points, P<.001). When controlling for differences in income, marital status, education, and improvements in urinary score, the impact on anxiety remained significant (P<0.05) at 3, 6, and 12 months. Based on previous analyses, these improvements are both statistically and clinically significant.
CONCLUSIONS: We found significant reductions in anxiety after local therapy. While these reductions were found in all men, AA and Hispanic men reported a greater reduction in anxiety compared to Caucasians. This suggests that AA/Hispanic men may have a different perspective regarding prostate cancer and treatment outcomes. Further work is necessary to elucidate this difference in perspective. Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e933
Source INTRODUCTION AND OBJECTIVES: While previous studies have evaluated the impact of malpractice caps on health care utilization and physician density, their effect on the adoption of innovative technology is unknown. We examined whether such caps impacted the national diffusion of minimally invasive radical prostatectomy (MIRP) for prostate cancer (PCa). For comparison we also examined trends in the diffusion of two technologies that antedate MIRP and are in their post-dissemination era: laparoscopic radical nephrectomy (LRN) and laparoscopic partial nephrectomy (LPN) for renal cell carcinoma (RCC).
METHODS: We identified patients 66 years with non-metastatic PCa between 2003-2011 in the SEER-Medicare database. Our cohort (n¼129,793) was classified based on the existence of a limit on non-economic damages in their geographical locations: states with a cap before and through our study period (cap states), states without cap before and through the study (non-cap states) and states whose cap was introduced during our study period (late-cap states). Multivariable logistic regression models were fitted to examine the influence of 0 cap 0 status on MIRP adoption while controlling for demographic and tumor characteristics. A similar analysis was performed for patients with non-metastatic RCC undergoing LRN and LPN.
RESULTS: Median age (IQR) of our PCa cohort was 74 years (70-79 years). 84% were White; 97% had T1/ T2 disease and 52% had high-grade disease. 17% were treated with radical prostatectomy (RP): 8.1% with MIRP and 8% with open RP (0.9%-unknown). Adoption of MIRP was quicker in cap-states than in non-cap and late-cap states (p<0.0001, Figure 1) . On multivariable analysis, there was a 70% higher likelihood of receipt of MIRP in patients in a cap-state compared to a non-cap state (OR: 1.7, P<0.0001). In contrast to MIRP, the diffusion of LPN and LRN were not different between cap and non-cap states on multivariable modeling (P0.05).
CONCLUSIONS: In a contemporary national cohort of PCa patients, states with malpractice caps had higher MIRP adoption rates. Diffusion rates of background technologies (LRN, LPN) in their post dissemination phase were not different in such states, highlighting the primacy of malpractice caps in explaining the differential effect on MIRP diffusion rates. INTRODUCTION AND OBJECTIVES: Intermediate risk prostate cancer (IRPCa, Gleason 7 with PSA<20) patients often receive whole gland therapy, potentially exposing them to overtreatment and side effects associated with treatment. Focal therapy (FT) minimizes these risks while treating all clinically significant cancer. We aimed to determine the accuracy of multiparametric MRI (mpMRI) and fusion biopsy (Fbx) in selecting candidates for FT.
Source of Funding: None
METHODS: Clinical and pathology data was prospectively collected from IRPCa patients who underwent prostate MpMRI prior to radical prostatectomy (RP) . Patients were analyzed in two cohorts: those who received mpMRI with Systematic Biopsy (Sbx) alone and those who received combination mpMRI Fbx/Sbx. Patients were considered suitable for FT if they had IRPCa in only one lobe of the prostate with a corresponding mpMRI visible lesion on the same side. Poor candidates were patients found to have high risk cancer (Gleason 8-10), IRPCa bilaterally, or PCa lesions that crossed the midline. Good candidates were confirmed with whole mount pathology analysis performed.
RESULTS: 185 patients with IRPCA (median age of 61 (IQR 10) years and PSA 5.67 (IQR 4.5 ng/dl) were included in the study. 129 (69.7%) had MRI and combination Fbx/Sbx. There was no difference in age, PSA and race distribution between the two cohorts. 98 (53.0%) patients were considered good FT candidates based on preoperative MpMRI and biopsy findings. Whole mount pathology analysis confirmed 67.1% of FT candidates determined from pre RP information (31.9% of total IRPCa patients). A higher proportion of FT candidates determined by mpMRI and Fbx/Sbx was confirmed on whole mount than FT candidates determined by mpMRI and Sbx alone (73.8% vs 44.4%; p¼0.026). Failure on whole mount was due to Gleason upgrade in 25.0% of patients and due to presence of bilateral IRPCa in the rest. On regression analysis, low PSA was the sole predictor of confirmed FT candidates on final pathology (p¼0.021).
CONCLUSIONS: MpMRI Fbx/Sbx is a more accurate tool than mpMRI with Sbx alone for predicting FT candidates. However, the application of mpMRI and Fbx/Sbx criteria to predict FT candidates may result in undertreatment of approximately one quarter of the patients with significant cancer. More accurate predictive capability is needed before FT can be offered to all patients with IRPCa.
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